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Biochemical tests have been the basis for investigations
of disorders affecting steroid hormones. In recent years it has
been possible however to study the genes that determine
functional enzymes, cofactors, receptors, transcription factors
and signaling systems that are involved in the process. 
Analyses of mutations are available as a diagnostic service for
only a few of these genes although research laboratories may
be able to provide a service. Both biochemical and genetic 
research have brought to light new disorders but for some 
patients a precise diagnosis may still not yet be achieved. 
Some genes for transcription factors involved in the 
development of the endocrine organs have also been 
identified and patients with defects in these processes have
been found. Specific points about the steroid assays will be
covered in a separate review. In general there is a lack of 
harmonisation of assays, an issue of concern which needs to
be addressed. Where hormone concentrations are given in
this review as action points  these should not be used 
without reference to local experience and reference ranges
for the analytical method in use. Tandem mass spectrometry
is likely to replace the immunoassay procedures for steroids
now being widely used; reference values are in general lower
than has been the case before now. As with all endocrine 
investigations, there are few single measurements that 
provide a definitive answer to a diagnosis. Timing of samples
in relation to age, gender and time of day needs to be 
considered. Appropriate reference ranges are needed. The 
regulation of a steroid needs to be taken into account. Test
protocols should be agreed with the laboratory and adhered
to in clinical practice. The laboratory should be given 
information about other drugs in use and clinical status of the
patient (eg hypotensive). Any result that is unexpected should
be discussed with the laboratory to exclude a procedural 
anomaly. A patient should be assessed clinically and 
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tests will confirm the basis of the condition and provide a 
basis for treatment and genetic counseling. In some cases
functional studies are needed to determine the effect on 
protein activity. Further genetic diseases may come to light
from research based on patients with unusual clinical signs.
Cortisol Hypersecretion
High plasma concentrations of cortisol lead to combinations
of a number of typical signs - moon-shaped face, buffalo
hump, striae. The disease caused by a pituitary adenoma
secreting adrenocorticotrophic hormone (ACTH) was first
described by Cushing. This form is more frequent in boys
than girls (1). Other causes of cortisol excess are classified
under the generic name of Cushing’s syndrome (Figure 1).
Use of exogenous corticosteroids is the commonest cause
of such problems and this should be excluded before 
investigations are taken further. Growth retardation and 
weight gain are the more likely presentation in a child with
Cushing’s syndrome. The high production of other steroids
(more typical of adrenal tumours) accounts for acne, 
hirsutism, and in some cases for hypertension, although it is
difficult to exclude direct effects of cortisol on blood pressure. 
Testing for Cushing’s syndrome first requires the 
demonstration of excess cortisol production and then 
establishing the degree of autonomy of this production (2-4).
Total cortisol concentration can be raised if CBG is elevated,
for example, with exogenous oestrogens. A raised 24 hour
urine excretion rate of free cortisol is a good indicator for the
condition. This is commonly requested in the investigation of
an obese patient. In addition to the methodological 
considerations of quantifying free cortisol in urine, there are
the problems of obtaining complete 24 hour urine collections,
especially in children. A high cortisol excretion rate may 
reflect stress on the day of collection, but in children the 
effects of alcoholism and psychiatric disorders seen in adults
are unlikely. 
Even if the urine cortisol excretion is clearly elevated 
(typically >400 nmol/24 hours), in the majority of patients 
tested, the urine free cortisol excretion will suppress to the
lower region of the normal range after taking 0.5 mg of 
dexamethasone every 6 hours for 2 days. The urine collection
is made on the second day of treatment. Children less than
40 kg should get a dose of 30 micrograms per kg per day (5).
Serum or plasma cortisol concentrations can be measured at 
0800-0900 h after taking 1.0mg of dexamethasone at 
2300h as an alternative to this urine test. In children the 
dexamethasone dose is 0.3 mg per metre squared (6). 
Plasma cortisol results above 50 nmol/L are abnormal. 
Accelerated dexamethasone metabolism is however, seen in
patients taking certain medications, particularly anticonvulsants.
In this regard, the simultaneous measurement of cortisol and
dexamethasone can improve the diagnostic precision of the
test. In a patient with high clinical suspicion of Cushing’s, but
normal urine free cortisol excretion rate on the first occassion,
repeated 24h urine collections over many weeks may be 
necessary since cyclical forms of the  disease have been 
characterized, at least in adults,  in this way with peak 
frequency over  weeks to months.
The pattern of cortisol secretion in Cushing’s syndrome is
such that there is a loss of the diurnal rhythm of the serum
concentrations of cortisol with noteably high levels in samples
taken at midnight. In adults saliva samples have been used,
but this has not been validated in children (1,7). Further 
biochemical tests and imaging procedures are justified at this
stage. The protocol will vary between hospitals depending
upon the laboratory services, clinical practice and experience,
and according to the availability of specialised tests eg ACTH
assay, CT scanning.
Measurements of the plasma ACTH concentrations at
midnight and 0800 hours are invaluable in the distinction of
Cushing’s syndrome. Circulating ACTH is low in patients with
iatrogenic Cushing’s or an adrenal tumour. In the ectopic
syndrome, the serum ACTH measured by RIA is often very
high. In considering assays for ACTH, the specificity of the 
RIA or IRMA should be known with respect to the 
measurement of ACTH itself, POMC and proACTH. The
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Figure 1. Adrenal steroid excess
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are found at high concentrations in patients with ectopic 
tumours (8). Chromagranin A may prove to be useful in the
differentiation of ectopic tumours (9).
If ACTH assays are not available, dynamic tests can be
used to gain further indications for the pathology of a patient
with high cortisol production. An adrenal tumour will not 
usually respond to an ACTH stimulation test with an 
increased steroid output, but a hypersecreting adrenal will
respond with a significant rise in serum cortisol concentrations.
In contrast to the ACTH stimulated adrenal which secretes
largely cortisol, adrenal tumours produce a spectrum of 
steroids such as dehydroepiandrosterone (DHA) or 
17-hydroxy pregnenolone or other steroids and measure-
ments of these, specifically or generally, can be arranged
through specialised centres. Analysis of steroids in urine
using capillary column GC and with mass spectrometry 
(urinary steroid profile analysis) may thus be the simplest
way to reveal complex patterns of steroid production associa-
ted with tumours.  This test an also confirm normal adrenal
function should a mass be an incidentaloma. CT scanning
may localise an adrenal tumour or display hyperplasia. Benign
adrenal lesions associated with Cushing's syndrome are 
linked with dysregulation of cyclic AMP signaling, whereas 
tumours are linked to insulin-like growth factor II, p53 protein
and related proteins (10).
The diagnosis of pituitary dependent Cushing’s disease is
confirmed when previously high cortisol production is 
substantially suppressed with high doses of dexamethasone 
(2 mg 6 hourly for 2 days) (1). Plasma cortisol, ACTH and 
urine free cortisol (or better of total cortisol metabolites) 
should all fall to less than 50% of their basal values in the 
majority of affected patients. In a meta-analysis of 3 tests
(UFC, dexamethasone suppression and midnight cortisol 
alone and in combination) was effective in the diagnosis of
Cushing's syndrome (11). Up to 10% of patients with ectopic
ACTH secreting tumours can, however, suppress with the
high dose of dexamethasone. The plasma concentrations of
potassium and ACTH should therefore be checked since
hypokalaemia and very high ACTH values by RIA are 
characteristic of the ectopic tumour. Other ectopic tumours
such as carcinoid may not always be associated with 
hypokalaemia and ACTH may be only moderately raised.
Hypokalaemia is found in a majority of cases with ectopic
ACTH tumour. These cases are rare in children. The adrenals
are enormous on CT and cortisol production is usually 
grossly elevated. A patient with an ectopic ACTH tumour
may present with rapid onset weight loss, oedema and
muscle weakness which is not the classical clinical picture of
Cushing’s syndrome.  
The common failure to distinguish the pituitary 
dependent from the ectopic ACTH secreting tumour and 
fear of the consequences of incorrect surgery are the 
reasons for the interest in further tests. If a pituitary adenoma
is suspected a CRF test may be informative in many cases
(1). In Cushing’s disease there is often an increase in cortisol
above the normal response to intravenous 100 μg CRF (1 μg
per kg in children). Blood samples are taken at 15 min 
before the CRF then at 0, 15, 30, 45, 60, 90 and 120 
minutes. The combination of high dose dexamethasone and
the CRF test with measurement of serum cortisol is superior
to either test alone in the differential diagnosis of Cushing’s
syndrome. The interpretation of this test in children is 
confounded by severe obesity (12). Simultaneous 
measurements of ACTH and cortisol may improve the 
sensitivity and specificity of the test (8,13). If an ectopic 
tumour is suspected, the pancreas and chest should be 
scanned by MRI, but it has to be said that the primary 
tumour is not always found (1). Venous catheter studies for
the localisation of tumours producing ACTH may be valuable.
The measurement of tumour markers such as CRF and 
calcitonin should be considered.
Sampling of blood bilaterally from inferior petrosal 
sinuses (BIPSS) for simultaneous assessment of ACTH 
concentrations is now used in older children in some 
specialised centres to differentiate Cushing’s disease from
the syndrome and for lateralisation of microadenoma (14). An
intriguing observation from these studies has been the 
parallel increased secretion of prolactin, growth hormone,
TSH and glycoprotein α-subunit.  These findings may reflect
changes in the vasculature or a paracrine effect of β-endorphin
from the tumour on adjacent tissue.  
Primary nodular adrenocortical hyperplasia is an 
mportant cause of Cushing’s syndrome in children and is
usually associated with multiple endocrine neoplasia or 
Carney complex (15,16). A paradoxical increase in UFC in the
second phase of the high dose dexamethasone suppression
test can be diagnostic (17,18). McCune-Albright syndrome
presents with Cushing’s syndrome in children along with 
polyostotic fibrous dysplasia, café-au-lait skin pigmentation
and precocious puberty (19). The syndrome is caused by 
activating mutations of the G protein alpha subunit (20).  
Cortisone reductase deficiency is a rare cause of increased
cortisol production because cortisone is not reduced to 
cortisol in the periphery. Patients present with a polycystic
ovary picture without weight gain. Adrenal androgen output
is raised because of the adrenal hyperplasia from high ACTH
stimulation. Mutations can be found in the HSD11B1 gene
and hexose-6-phosphate dehydrogenase (H6PDH) which is
involved in NADPH regeneration for the enzyme (21). A urine
steroid profile shows higher excretions of 11-oxo than 
11-hydroxy cortisol metabolites (high ratio of THE plus 
cortolones to THF, allo-THF and cortols). A cortisone acetate
challenge test is recommended to provide evidence to 
support the defects (22). Cortisol generation is lower than
normal in patients with reductase defect.
High plasma cortisol concentrations and production rate
can be seen in familial glucocorticoid resistance. Patients
display signs of androgen and mineralocorticoid excess 
without the glucocorticoid effects (23,24). Teenagers with
resistant hypertension can show biochemical features of
cortisol resistance (25), but so far the genetic basis of this
has not been proven. 
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Adrenal insufficiency may result from primary adrenal 
failure or secondary disease to impairment of the hypothalamic-
pituitary-adrenal axis (HPA) (26) and is life-threatening (27,28).
Although Addison in 1855 described tuberculous destruction
of the whole adrenal glands, today autoimmune adrenalitis
which spares the adrenal medulla is more common. In 
children, adrenal function is commonly impaired after 
long-term treatment with corticosteroids such as for asthma.
This is an important clinical problem requiring tests, although
there is no agreement on which tests should be performed.
Morning plasma cortisol, urine free cortisol and cortisol 
response to ACTH are often used. Urine free cortisol is, 
however, a very poor test of adrenal suppression and 
measurements of total cortisol metabolites is much better
(29). Congenital adrenal hyperplasia (CAH) is a common 
cause of primary adrenal insufficiency that can be missed
(28,30-32). Newborn screening based on determinations of
blood spot 17-hydroxyprogesterone concentrations should
pick up the 21-hydroxylase deficiency. A rapid result is needed
to return an abnormal result before the onset of an adrenal 
crisis (presenting usually 5-10 days after birth). Hyperkalaemia
before hyponatraemia can be early signs of CAH, prolonged
jaundice in a newborn infant may also be a sign of adrenal 
insufficiency. Other rare causes of adrenal insufficiency 
include infarction or haemorrhage and adrenal hypoplasia 
(particularly in newborn infants). Later adrenal destruction by
metastases, sarcoidosis, histoplasmosis and amyloidosis may
be found. Patients may have few or no symptoms of adrenal
cortical insufficiency until they suffer a physical stress such as
trauma, surgery or infection when they present with tired-
ness, weakness, lethargy, anorexia, nausea, weight loss, 
dizziness and hypoglycaemia. Pigmentation will sometimes
be noted as a smokey brown coloration which affects the 
buccal mucosa (inside cheeks, gums and lips), on skin 
creases, scars, genitalia and areolae. This is a reflection of 
melanocyte stimulating hormone action which is a product of
the proopiomelanocortin secreted by the pituitary along with
ACTH. The patient will probably have postural hypotension
with high plasma renin activity (PRA). The differential diagnosis
of hypoglycaemia in childhood should include adrenal cortical
insufficiency. This can be due to congenital adrenal hypoplasia
(33) due to a primary defect in adrenal development or defects
in ACTH synthesis, processing, release and response (familial
glucocorticoid deficiency) (34). 
Adrenal insufficiency is seen in disorders of cortisol 
production.  Congenital adrenal hyperplasia in children often
presents with symptoms due to excess or deficiency of sex
steroids. Defects of 21-hydroxylase, 11β-hydroxylase and 
3β-hydroxysteroid dehydrogenase are found with decreasing
frequency and will be considered in more detail later in the
review. Recently, an apparent combined deficiency of 
21-hydroxylase and 17-hydroxylase was attributed to a defect
in a common electron transporter called cytochrome P450
oxidoreductase (POR; ORD) (35-37). This defect can be 
associated with the Antley-Bixler syndrome.  A raised 
17-hydroxyprogesterone is suggestive of 21-hydroxylase, 
other steroids (progesterone and corticosterone) need to be
checked if a POR defect is likely.  A urine steroid profile is
again a valuable test to cover these possibilities (38-40). 
Congenital adrenal hyperplasia due to defects of cholesterol
uptake and cholesterol side chain cleavage enzyme
(CYP11A1) (41,42) can be lethal at an early stage, but there
are exceptions (43) some present with hypospadias.  The 
infants present as phenotypic females and have an adrenal
crisis in the newborn period.  Cholesterol uptake into 
mitochondria requires Steroidogenic Acute regulatory protein
(StAR) and many mutations have been found in the gene
(44,45). Analysis of the genes involved in CAH has been 
critically reviewed (32) and will not be described in detail 
here. CYP21A2 mutations in Turkish children were summarized
in this Journal (46). Several of the genes are duplicated on a
chromosome to give active and inactive pairs (CYP21A2 and
pseudogene CYP21B2), enzymes of different function 
(11-hydroxylase for cortisol synthesis - CYP11B1 and for 
aldosterone synthesis - CYP11B2) and enzymes of different
tissue expression (HSD3B1 in periphery and HSD3B2 in 
adrenals and gonads).  Care must be taken in the genetic
tests to demonstrate mutations.  Restriction enzyme digests,
Southern blotting, polymerase chain reactions, specific 
oligonucleotide hybridization techniques, sequencing have
been used. 
A number of disorders of adrenal and gonadal development
have been characterized in recent years. They present 
clinically and biochemically with inadequate or absence of 
adrenal and/or gonadal steroids. These include in boys 
defects of nuclear receptors DAX-1 and SF-1. Mutations in
the NROB1 gene are found in the dosage sensitive sex 
reversal adrenal hypoplasia congenita on the X-chromosome,
in the gene 1 (DAX-1) lead to neonatal adrenal insufficiency
and failure to undergo puberty with hypogonadotrophic 
hypogonadism  (47-51). Steroidogenic factor 1 (SF-1), a 
nuclear receptor, is expressed in adrenals and gonads, and
mutations in the gene are found in some patients that 
present with adrenal failure and 46XY DSD (52-54).
The ACTH receptor gene (MC2R) has been found to have
mutations in infants that present with glucocorticoid but not
usually mineralocorticoid failure (55,56). Mutations that 
inactivate proopiomelanocortin (POMC) have been described
in children with adrenal insufficiency, early onset obesity and 
sometimes along with fair skin and red hair (57). Other 
pituitary transcription factor genes can be affected (PROP1,
HESX1, OTX2, LHX4, SOX3) (see Reference 26 for recent
summary), and others will come to light in the course of time.
Indications of Addison’s disease in young males should
prompt consideration of adrenoleukodystrophy (58,59). 
Elevated levels of very long chain fatty acids (VLCFA) are 
found in plasma.  Neurologic problems may or may not be
present. The achalasia-Addisonian-alacrima syndrome (AAA),
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of combined adrenal and neurologic (autonomic) 
involvement (60). A gene for aladin on chromosome 12q3 is
involved (61). Smith-Lemli-Opitz syndrome may present as
ambiguous genitalia, and distinctive facial features, small 
head size (microcephaly). Malformations of the heart, lungs,
kidneys, and GI tract are also common. Infants with Smith-
Lemli-Opitz syndrome have weak muscle tone (hypotonia),
experience feeding difficulties, and tend to grow more 
slowly than other infants. Most affected individuals have 
fused second and third toes (syndactyly), and some have 
extra fingers or toes (polydactyly). A defect in cholesterol
synthesis has been found and delta-7 steroids/sterols can be
elevated in blood and urine (62,63).
A good algorithm for the investigation of primary adrenal
insufficiency in children has been published from the 
Department of Pediatrics in Montreal, Canada (30).  Plasma
cortisol concentrations between 7 and 9 am that are 
repeatedly less than 170 nmol/L are suggestive of adrenal 
cortical insufficiency. In a sick child cortisol concentrations of
300 nmol/L that do not increase on synacthen should be 
regarded as innappropriately low and worth investigating.
This may not be seen, however, until the course of the disease
has advanced.  Low concentrations of cortisol in saliva also
reflect Addison’s disease (64). A short Synacthen test should
be performed to assess adrenal reserve.  Blood for serum 
cortisol is taken before and at 30 and 60 minutes after an 
intravenous injection of 250 micrograms of soluble Synacthen.
Lower doses of synacthen (62.5 or 125 micrograms) should
be used in young children. A normal response is characterised
by an increment in cortisol of at least 200 nmol/L or a rise to
levels above 500 nmol/L. If an assay for cortisol is specific
enough to exclude cross reaction with prednisolone this
synthetic steroid can be given immediately after the basal 
blood has been taken so as to afford glucocorticoid cover 
without affecting the adrenal response to exogenous ACTH.
If there is pigmentation, the patient has primary adrenal 
failure (Addison's disease). Plasma ACTH measurements will
be raised in Addison's disease and normal or low in secondary
adrenal failure.  A metyrapone test or insulin tolerance test
can be helpful in distinguishing primary from secondary 
adrenal insufficiency. Circulating antibodies to the adrenal 
cortex suggest an autoimmune process and other endocrine
tests may be required to look for an extension of the 
autoimmune process to other hormonal tissues. Cortisol 
should be replaced at 9-12 mg/M
2/24h and it is useful to check
cortisol concentrations throughout the day in plasma samples
taken at 30 minute intervals over 2 hours after a morning 
dose of  hydrocortisone, then at 2 to 3 hour intervals 
throughout the day.  Depending on the frequency of 
sampling, cortisol concentrations above 700 nmol/L within an
appropriate pattern reflects adequate replacement therapy.
Hyponatraemia is a frequent finding in primary adrenal 
insufficiency due to loss of mineralocorticoid steroids.  The
low plasma sodium is associated with hyperkalaemia and a
raised plasma urea.  In the urine there will be low potassium
loss.  In some cases the adrenal insufficiency may be part of
more general hypopituitarism. If hypocortisolism is due to
ACTH deficiency resulting from pituitary or hypothalamic 
disease such as tumours, infarction, trauma, there are usually
other signs of deficiency of other hormones (eg loss of body
hair). There will be no pigmentation. In the absence of ACTH,
the production of aldosterone under the stimulus of the 
renin-angiotensin system will usually be unaffected and the
blood pressure will probably be normal. Secondary adrenal 
insufficiency occurs when the adrenal cortex is deprived of
ACTH stimulation.  The commonest cause is after steroid
therapy.  An expanding pituitary tumour which leads to 
impairment of pituitary function usually affects the pituitary
hormones in a sequential manner over a period of time.
Growth hormone secretion fails first, followed by 
gonadotrophins, TSH and ACTH (65).  
Mineralocorticoid Excess
Primary aldosteronism is extremely rare in children (66).
Increased aldosterone secretion may be suspected in a 
patient presenting with muscle weakness due to hypokalaemi-
a and headaches due to hypertension. Before the laboratory
enters investigations of the renin-angiotensin-aldosterone
system, abnormalities of electrolytes and water balance 
need to be confirmed. Many anti-hypertensive drugs affect
plasma renin and aldosterone (thiazide and loop diuretics, 
beta-receptor blockers, calcium channel blockers) and these
should ideally be stopped two weeks before meaningful
tests can be carried out.  Conn was the first in 1956 to 
describe an adrenal adenoma secreting aldosterone. The 
diagnosis of primary hyperaldosteronism rests in finding plasma
aldosterone concentrations high for the corresponding PRA.
Since removal of an adenoma corrects the blood pressure, 
localisation of the source of aldosterone assists a decision on
the surgical approach for the operation. 
Blood samples must be taken on several occasions 
for measurement of electrolytes.  Patients with primary
hyperaldosteronism have in the past been considered for 
investigation only when repeated plasma potassium values
were below 3.7 mmol/L. This is now not the case. Causes for
potassium depletion (diarrhoea, purgatives, liquorice ingestion,
diuretics) must be excluded. An algorithm for the diagnosis of
primary aldosteronism in adults can be followed to reach a 
diagnosis of a rare paediatric problem (67). The tests should
be conducted under medical supervision. Not all tests have
been validated in children and may be difficult. A tumour may
accumulate radiolabelled cholesterol. Catheterisation of the
adrenal veins is in some centres a successful procedure in
adults, but the venous drainage of the adrenal glands is often
complex and even an experienced radiographer is not 
guaranteed of success. In a patient with an aldosterone 
secreting adenoma, the adrenal venous serum from the 
affected side usually shows a higher concentration of 
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vein or the periphery sampled simultaneously. Aldosterone
and cortisol should be measured in all samples to check the
authenticity of the site from which the blood is taken. 
The cortisol concentrations in the adrenal vein samples 
may be in the order of 6000 nmol/L. In children, idiopathic
hyperaldosteronism in which the adrenals have a micro-
or macronodular hyperplastic appearance has been described
(68,69). Surgery is not curative. The best treatment is with
the aldosterone antagonist, spironolactone, or with amiloride. 
Glucocorticoid remediable hyperaldosteronism is a rare
familial cause of hypertension in which the biochemical 
features of hyperaldosteronism and the hypertension 
respond to glucocorticoid (dexamethasone) treatment (70).
The hyperaldosteronism is responsive to ACTH but not to 
angiotensin II. This condition is associated with increased 
excretion of 18-oxocortisol which may arise by 18-hydroxylation
of cortisol in the adrenal zona fasciculata due to a protein
from a chimeric gene of CYPB11B1 and CYP11B2 (71). 
Estimation of 18-hydroxycortisol is likely to prove useful in
screening for this disorder (72,73), but this assay has limited
availability. An increased urine excretion of the steroid can be
seen in a urine steroid profile. Genetic testing is available (74).
Diuretic therapy is the commonest cause of secondary 
aldosteronism. PRA is raised as a physiological response to
hypovolaemia (haemorrhage or intestinal fluid loss). Renin 
secretion is increased with renal ischaemia, renal artery 
stenosis. Peripheral PRA levels may be only moderately 
raised, but renal vein samples may show a result on the 
ischaemic side 1.5 times or more that from the contralateral
normal kidney.
Hypokalaemia without hypertension is the result of 
increased aldosterone, but certainly in adults can be due to
diuretic or laxative abuse or psychogenic vomiting. Salt loss
with hypokalaemic alkalosis and hypercaliuria are found with
renal tubulopathies (Bartter syndrome) in the distal convoluted
tubules and/or loop of Henle  (75). An infant with polyhydram-
nios may have one form of Bartter’s syndrome needing 
genetic analysis to distinguish them (76). Hypokalaemic 
alkalosis is due to a renal tubular defect from a mutation in
the renal outer medullary potassium channel (Type 2 ROMK
now KCNJ1) or the sodium/potassium/2 chloride transporter
(Type 1 SLCl2A1 now NKCC2). The infantile form is associated
with growth failure and sensorineural deafness. The primary
cause for this disorder (type 3) is due to mutations in the 
chloride channel gene (CLCNKB) (76). Type 4 has simultaneous
mutations in BSND and CLCNKB or CLCNKA. There is 
resistance of the vasculature to the pressor action of 
angiotensin II associated with a compensatory increase in
PRA with juxtaglomerular hyperplasia. The plasma concentra-
tions of both aldosterone and PRA are raised. The Gitelman
variant can present in childhood with growth delay, metabolic
alkalosis, hypokalaemia and hypomagnesaemia. Mutations
are found in the chloride transporter SLCl2A3 gene (77).
Low PRA may be encountered when mineralocorticoids
other than aldosterone are in excess. This can be due to CAH
due to 11β-hydroxylase deficiency or 17α-hydroxylase 
deficiency (11-deoxycorticosterone DOC excess) (31,32,78)
or with mineralocorticoid secreting tumours. All are rare. A
defect in CYP11B1 presents with ambiguous genitalia in girls
and precocious puberty in boys (79). 17-hydroxylase 
deficiency is not usually detected until a female is investigated
for primary amenorrhoea and lack of sexual development.
Persistent high progesterone is a useful diagnostic clue to
this defect (80). The increased plasma corticosterone 
concentrations have been demonstrated by HPLC with UV
detection (81). In a syndrome of apparent mineralocorticoid
excess (AME) there is hypertension, hypokalaemia and 
reduced secretion rate of cortisol.  The improvement brought
about by treatment with spironolactone (aldosterone 
antagonist) or triamterine (potassium sparing diuretic) 
suggested the presence of an unidentified mineralocorticoid.
The disease is attributed to cortisol acting as both glucocorticoid
and mineralocorticoid with a prolonged half-life due to low 
activity of 11β-hydroxysteroid dehydrogenase type 2 (which
normally oxidises cortisol to  inactive cortisone) (82). This 
defect is most easily detected by a urine steroid profile which
clearly displays a high excretion of cortisol metabolites relative
to cortisone (83). Tandem mass spectrometry methods have
enabled simultaneous analysis of cortisol and cortisone in
blood (84-86) and saliva (87), and of metabolites in urine (88).
The disease has been found mainly in children with severe
hypertension and may be lethal which may explain why very
few adult cases have been described. The mineralocorticoid
activity of liquorice is now known to be due to inhibition of
the enzyme system 11β-hydroxysteroid dehydrogenase. 
Patients should be asked about confectionary habits (89).
Primary hypoaldosteronism with hyperkalaemia, 
increased PRA and low aldosterone concentrations is due to
Addison’s disease, congenital adrenal hypoplasia, or defects
of aldosterone synthesis most commonly due to CAH. PRA
and aldosterone are rarely subnormal, but this secondary
hypoaldosteronism is found in association with diabetes,
chronic renal disease and as an isolated occurrence.
Hyponatraemia in the neonatal period is an urgent 
diagnostic problem which should consider whether the 
sodium intake is adequate (<4 mmol/kg/day in term babies,
up to 12 mmol/kg/day in preterm infants), the water intake is
high or there is sodium loss from the gastrointestinal tract or
kidneys. Renal salt loss can be due to anatomical abnormalities,
obstructive or renal tubular disorders which can include failure
to respond to aldosterone. Low production of mineralocorticoid
due to adrenal disease is a common cause of salt loss with
hyperkalaemia in newborns.
A male child who collapses during the second week of 
life should be tested for CAH due to 21-hydroxylase 
deficiency. Sixty percent of all children with this defect show
this salt-losing variant of the disease. The enzyme deficiency
in cortisol production extends to the synthesis of aldosterone.
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inappropriately low. Since plasma renin activity is higher in all
newborn infants than in adults it is important to check the 
activity against a normal range for age of the infant (90). 
A defect in 3β-hydroxysteroid dehydrogenase, side-chain 
cleavage, StAR or adrenal hypoplasia may also explain the
salt-losing state so other tests such as a urine steroid profile
should be organized. 
If the biosynthetic path to cortisol is normal, the production
of aldosterone needs to be evaluated. Defects of aldosterone
production and action are recognised. In both cases PRA will
be elevated, the defects are distinguished by the serum 
concentrations of aldosterone or urine excretion rates of the
metabolites. A defect in the late steps of aldosterone 
biosynthesis will be confirmed when 18-hydroxycorticosterone
production is shown to be elevated in blood (91) or urine (92).
Mutations have been found in CYP11B2 by sequencing (93).   
Corticosterone, 18-hydroxycorticosterone and aldosterone
are elevated through renin/angiotensin stimulation in 
disorders of aldosterone receptor and the gene NR3C2 
encoding the mineralocorticoid receptor can have mutations
in  some (pseudohypoaldosteronism - PHA) (94-97). This is an
autosomal dominant form of PHA1. A more common form is
due to mutations of the epithelial sodium transport channel
(ENaC) (98,99). The biochemical diagnosis is straightforward
if the child is sodium depleted (100). In children with the 
receptor defect the salt loss seems to be partially correctable
by increasing the dietary salt intake to satisfy salt craving. 
Aldosterone receptor resistance has been demonstrated in
assays of electrolyte transfer by mononuclear leucocytes
(101), but this is not generally available.   
Hyponatraemia is often seen in the first weeks of life in
preterm infants (<30 weeks gestation) (102). This reflects 
immaturity of renal function as well as in the adrenal 
production of aldosterone and the diuretic effect of increased
vasopressin production (103,104).
Androgen Excess
The investigations of androgen excess have different
objectives depending on the age and karyotype of the 
patient. Thus 46,XX girls present with ambiguous genitalia
usually due to inherited metabolic disease (congenital 
adrenal hyperplasia, CAH) of the adrenal cortex. During
childhood boys with precocious puberty may have space
occupying lesions of the brain, CAH or very rarely tumours
of the adrenals or gonads. A few girls with hirsutism and/or
acne with or without menstrual disturbance may have 
non-classic CAH or very rarely have excess secretion of 
androgens of ovarian or adrenal origin due to tumours.
Polycystic ovaries are commonly found in mild hyperandro-
genisation in adolescence that may progress to infertility in
adult life.
In newborn girls with ambiguous genitalia (46XX DSD),
the commonest cause is due to enzyme defects of cortisol
synthesis with diversion of intermediates to androgen 
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Figure 2. Androgenised female 46XX
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metabolitesproduction  (31,32) (Figure 2). The genotype should be 
confirmed by chromosome analysis. A pelvic ultrasound may
also be helpful, but results need to be treated with some 
caution. Other external causes of a virilised female are 
attributed to aromatase deficiency (105) and an ovotesticular
DSD (106), maternal ingestion of progestogens (now very 
rare) or androgens or to maternal production of androgens by
an adrenal or ovarian tumour. In these cases, the child will 
have normal endocrinology after birth, but may need surgery
on the external genitalia if androgenisation is severe.
A reduction in steroid 21-hydroxylase activity or absence
of 11β-hydroxylase or 3β-hydroxysteroid dehydrogenase can
be the cause of CAH of which 21-hydroxylase deficiency is
by far the commonest cause of CAH (90% of cases). In 
Europe, 60% of all cases of steroid 21-hydroxylase deficiency
will present in the newborn period with a salt-losing crisis.
This reflects the nature of the enzyme block. If there is a 
salt-losing crisis, this will need immediate treatment.  An 
increase in serum potassium may be seen prior to a fall in
body weight and hyponatraemia. 
17α-hydroxyprogesterone is a biosynthetic precursor of
cortisol and in patients with deficiency of 21-hydroxylase the
production of 17-OHP increases and serum levels are 
elevated. The reduced capacity to produce cortisol, however,
leads to high ACTH levels which cause adrenal hyperplasia.
There is also a high adrenal secretion of androgens which
cause virilisation. The measurement of 17-OHP in serum,
plasma and blood spots is used for the diagnosis of this 
disorder. The timing of blood sampling is very important in 
order that the laboratory can interpret the findings. In all 
newborn infants, 17-OHP concentrations in serum are high
on the first day of life (>100 nmol/L) and the levels fall over
the first week to below 50 nmol/L. After day 3, there is 
usually good discrimination of the 17-OHP in affected cases
(100-800nmol/L) from normal infants (<15 nmol/L). Differences
in results with a direct and an extraction method would 
suggest that steroids in blood (probably steroid sulphates
from the fetal adrenal) cross react in the RIA giving higher 
results in the direct assay (107,108). The suggestion that 
steroid sulphates affect the quality of the assay is supported
on the observation of greater discrepancy between the 
results obtained by the 2 methods in premature and low birth
weight babies both of which have sustained fetal adrenal 
activity after birth. 17-OHP can be mildly elevated in defects
of HSD3B2, POR and CYP11B1.
In rare cases of CAH, the defect is due to low activity of
the 11β-hydroxylase enzyme (79). This defect is best identified
by a raised serum concentration of 11-deoxycortisol or by a
urine steroid profile. A high excretion of 6-hydroxy-tetrahydro-
11-deoxycortisol (6-hydroxy-THS) is a better marker of the 
defect in the newborn than THS which is elevated in older 
patients (>120 nmol/L) but not so clearly raised in the 
newborn period (109). This again emphasises the requirement
to involve specialised laboratories with relevant experience.
The cause of ambiguous genitalia in a newborn child is 
required as soon as possible in order to counsel anxious 
parents and start treatment. A 17-OHP assay which involves
solvent extraction before the RIA is essential. Now that 
specific urine metabolites of 17-OHP have been recognised,
the diagnosis by GC analysis of steroids in urine is reliable.
Pregnanetriol is one marker for the disorder in the newborn.
A characteristic urine steroid pattern can be recognised of
which the most informative steroid is 17α-hydroxypregnanolone.
It is essential that a laboratory offering this analysis can 
provide a rapid service (<2 days). In order to achieve this, the
identity of the steroids in the GC analysis must be confirmed
by a further analysis with GC coupled to a mass spectrometer.
Some laboratories now offer simultaneous analysis of 
several steroids by using GC-MS (110) or LC coupled with
tandem mass spectrometry (111-114). These tests enable
one of several forms of CAH to be detected and will become
important on regional or national basis. Newborn screening
has been based on immunoassay of steroids in blood spots.
Repeat testing has eliminated the disease when the 
concentrations of 17-OHP were lower than an initial high 
level that suggested 21-hydroxylase deficiency (115); this 
approach is stressful to the family. False positive results are
reduced by the use of cut-off levels adjusted for gestation
age or birth weight, and by solvent extraction of steroids
(116). Screening will also improve with more specific 
technology based on tandem mass spectrometry (117-119).
Once CAH has been confirmed and lifelong cortisol 
treatment has commenced, compliance is best assessed in
children by following growth (120). Height and weight should
be followed at 3 monthly intervals in the first 2 years of life,
then at 6 monthly visits. Bone age is checked yearly from 
X-rays of the wrist and hands. The replacement therapy 
should be adjusted according to body size. Hydrocortisone is
usually prescribed at 9-12 mg/M
2/day with 2/3 of the dose in
the morning and 1/3 in the evening. If fludrocortisone is 
given, to control salt loss it must be remembered that this
steroid is a potent glucocorticoid itself and the dose should
not exceed 0.15 mg/M
2. Sodium supplements may be 
needed in infancy. Electrolytes can be measured periodically,
but for long term assessment of mineralocorticoid 
replacement the measurement of plasma renin activity is 
advisable. The measurement of 17-OHP and androgens in
blood (or saliva) taken at regular intervals will define the 
adrenal steroid output in relation to treatment, but in practice
has little effect on a patients drug taking habits. Androstene-
dione measurements may be helpful in the management of
CAH due to 21-hydroxylase and 11β-hydroxylase defects.
Measurement of PRA can be used to monitor efficacy of 
treatment in salt-losing CAH. Patients with 21-hydroxylase
and some with 3β-hydroxysteroid dehydrogenase defects
manifest elevated PRA, while in the defects with mineralo-
corticoid excess (17α-hydroxylase and 11β-hydroxylase) PRA
is suppressed. PRA is normalised with effective treatment. In
the case of 21-hydroxylase deficiency and 3β-hydroxysteroid
dehydrogenase defects, treatment is improved with addition
of fludrocortisone.
216
Honour JW
Investigations of Steroid DisordersWhen sexual maturation appears before 8 years in girls
and 9 years in boys, puberty is considered precocious. The 
diagnosis of precocious puberty was reviewed recently in
this Journal (121). Normal puberty is initiated by an increase
in pulsatile secretion of GnRH at night, although the 
mechanism and timing of this initiation is still not understood.
Failure to find a pelvic mass by palpation or ultrasound scan
reduces the likelihood of a rare ovarian tumour. Central 
precocious puberty (gonadotrophin dependent precocious
puberty) reflects early activation of the gonadotrophic drive to
increased gonadal function. This is more common in girls
than in boys. A child with clinical precocious puberty who has
pubertal gonadotrophin levels and augmented nocturnal 
gonadotrophin secretion has central precocious puberty
(122,123). LH results should be treated with caution because
of interference from heterophilic antibodies and high results
should be confirmed using a second assay (124). Assays 
have been devised to avoid such interference (125,126). In
girls, pelvic ultrasound is useful for the assessment of central
precocious puberty (122). CNS tumours (hamartomas, third
ventricular cysts, astrocytomas or gliomas) can be 
recognised by MRI. Some of the tumours (dysgerminomas,
hepatoblastomas) secrete hCG. A cerebral tumour is 
relatively more common in boys with central precocious 
puberty than in girls.  
Gonadotrophin independent precocious puberty is due to
inappropriate production of gonadal or adrenal hormones
which affect secondary sex characteristics. Children may 
have acne and behavioural problems and may become taller
than their peers. As a result of rapid skeletal maturation 
there is early epiphyseal fusion and the outcome is for short
stature in adulthood. Hypothyroidism should be excluded.
With the increase in TSH there is a concomitant increase in
FSH and prolactin that presumably leads to sexual precocity.
In patients with the McCune-Albright syndrome, precocious
puberty is associated with cafe-au-lait skin marks and 
polyostotic fibrous dysplasia (19). Plasma gonadotrophin 
concentrations are often pubertal, but may in some cases be
prepubertal.  Symptoms may wax and wane and on ultrasound
this can be attributed to the appearance and regression of
unilateral ovarian cysts. Up to 80% of girls and 40% of boys
with precocious puberty may have no responsible cause and
are termed idiopathic.  
Pseudo-precocious puberty can be the result of exposure
to exogenous sex steroids. Both contraceptive pill and anabolic
steroids are reported offenders. Abnormal sex steroid 
secretion from tumours is also a cause.  The most common
adrenal tumour reported in the literature secretes DHAS. In
general the tumours have been quite large. A number of 
cases of tumours secreting other androgens have been 
reported and using urine  steroid profile analysis, the secretion
of 11β-hydroxyandrostenedione has  been defined on the 
basis of high excretion of 11β-hydroxyandrosterone
(127,128). In these reported cases androgen excretion was
not grossly elevated and without scanning of the adrenals a
tumour may have been dismissed. FSH and LH are suppressed
to within prepubertal ranges. The secretion of androgens by
adrenal tumours is not suppressed by giving dexamethasone.
A testicular mass with grossly elevated 17-OH-P usually 
indicates CAH with adrenal rests in the testes. Leydig cell 
tumours, however, may produce elevated 17-OH-P, which is
not suppressed with dexamethasone. 21-deoxycortisol is not
raised in these cases, unlike the situation with CAH. One 
recent report of premature pubarche described a child with
hyperandrogenic anovulation, who had low plasma DHAS 
due to defect of the sulphotransferase SULT2A1 through a
defect in sulphate delivery from PAPS through inactivating
mutations in PAPSS2 (129).
Pubic hair growth before breast development or testicular
enlargement may be the outcome of increased secretion of
DHA and DHAS from the adrenal cortex due to early 
differentiation of the zona reticularis. This is a benign 
disorder called premature adrenarche not requiring 
treatment. DHA and DHAS concentrations in serum should
be interpreted against normal ranges for age. Testosterone
may be slightly elevated for age due to peripheral conversion
of the adrenal androgens. The 24 hour urine excretion of 
androsterone, aetiocholanolone as well as cortisol metabolies
are above the normal range for age and body size (Figure 3)
reflecting advance adrenal growth. Premature adrenarche is
more common in Asian and Afro-Caribbean children than
Caucasians. 
Acne, hirsutism, menstrual disturbance can be due to
non-classical forms of CAH and a mild defect of the steroid
21-hydroxylase. In many such patients, the basal 
17-hydroxyprogesterone concentrations are above the nor-
mal range (>5 nmol/L). An injection of ACTH will lead to an
increase in serum 17-OHP at 30 and 60 minutes after the
trophic hormone injection and affected subjects will have
an increment in 17-OHP greater than seen in normal 
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Figure 3. Children with premature adrenarche
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4 5 6 7 8 9 10 11subjects (Table 1) (130). Fifty percent of patients with 
non-classic or late onset form of CAH have HLA B14, DR1
in association, since this is coded nearby on the short arm
of chromosome 6 and specific mutations in exon 1 or exon
7 CYP21A2 (V281L; P453S) (131). A late onset form of 
3β-hydroxysteroid dehydrogenase deficiency was suggested
on the basis of exagerated DHA or 17-hydroxypregnenolone
response to ACTH (132), but mutation analysis does not
support this aetiology (133,134).
Some girls present with isolated breast development
(premature thelarche) and no growth acceleration (135). 
Increased oestrogen production in girls with premature 
thelarche is a benign condition not to be confused with 
central precocious puberty. There is no increase in growth 
rate. The latter is more serious and causes progressive 
breast development with pubic hair growth, accelerated
growth rate and bone maturation and early epiphyseal fusion.
A pelvic ultrasound may show a follicle in the ovary. The two
conditions have been resolved by repeated blood sampling at
15 minute intervals throughout the night (122). In patients
with thelarche the FSH is higher (2-7 iu/L) than the LH 
(1-3 iu/L), which contrasts with precocious puberty where LH
secretion predominates. A GnRH stimulation test may 
sometimes be needed to distinguish the 2 disorders again by
revealing differences in the prodominant gonadotrophin, but
interpretation may be assay dependent (136,137). Various
doses of GnRH are used with 10 microgram and 100 
microgram (being the most common) with blood samples at
zero, 20 and 60 minutes. Peak LH usually occurs at 20 min
and peak FSH at 60 minutes after injection of GnRH.
Androgen Deficiency
Incomplete androgenisation of a 46XY fetus is due to a
failure of sex steroid production or to resistance to these
hormones because of receptor defects. Most laboratories
will need the help of specialised centres to resolve such
cases, although a number of investigations can be 
undertaken locally. Following confirmation of chromosomes,
the serum concentrations of cortisol and testosterone 
should be checked. From these results some clear 
decisions can be made. Defects of sex steroid production
can be separated into:
• those affecting cortisol and androgens and (Figure 4)
• those relating to androgens alone (Figure 5)
Poor androgenisation of a 46XY male (46XY DSD) with
low cortisol production can be attributed to defects of StAR,
cholesterol 20,22 desmolase (side-chain cleavage,
CYP11A1), 17α-hydroxylase deficiency, or of 3β-hydroxy-
steroid  dehydrogenase type 2 (Figure 4). These enzymes
affect the production of all important adrenal and gonadal
steroid hormones and disorders of the enzymes are often
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Figure 4. Poorly androgenised male, low cortisol (* can be ≥150 nmol/L unwell)
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9q.33fatal for the child, so that few cases are documented in the
literature. StAR deficiency is also called lipoid adrenal
hyperplasia on account of the histological appearance of the
adrenals at post mortem reflecting the ACTH stimulated 
adrenal which cannot produce cortisol nor process cholesterol.  
Defects of 17α-hydroxylase (78,81,138) and 3β-OH-S-DH
are identified biochemically by demonstrating high serum 
levels and urine metabolites of the respective enzyme 
substrates (Table 1). The pattern of steroids in urine of a 
neonate, later confirmed to have 17α-hydroxylase deficiency,
showed high excretion rates of 16α-hydroxypregnanolone.
At 15 months of age the child excreted corticosterone 
metabolites just as is found in urine of adults with this 
disease (139). Mutations in CYP17 have been confirmed by
sequencing (78,81,138,140). A 3β-hydroxysteroid dehydroge-
nase deficiency is in practice difficult to confirm in a newborn
child because the markers for the defect (DHA and 
pregnenolone) are normal products of the adrenal in the 
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Figure 5. Poorly androgenised male, normal cortisol production (N.B. cortisol cut off can be > 300 nmol/L if unwell)
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> 150 nmol/Lnewborn due to inactivity of this enzyme in the fetal adrenal
cortex. A 24 hour urine collection with determination of 
excretion rates of all steroids is therefore needed. Since 
these infants are usually very sick, this is not straightforward.
Plasma measurements of DHA and ACTH may be better
tests before treatment, but in the face of an adrenal crisis
replacement therapy may be needed before the necessary
tests are completed. To overcome this problem dexametha-
sone is the preferred treatment. If a child suspected of 
having 3β-hydroxysteroid dehydrogenase deficiency is switched
to treatment with dexamethasone and fludrocortisone then
given daily injections of depot ACTH (Synacthen), the 
markers for the defect can be displayed in the urine steroid
profile without interference from dexamethasone. This 
approach has been used successfully in confirming 
3β-OHSDH deficiency during maintainance with hydrocortisone
for several years, although ACTH was needed for several
days before the suppressed adrenal secreted sufficient 
steroid to be detected in the urine steroid assay. Males with
defects in HSD3B2 can be reared as boys needing adrenal
steroid replacement with the addition of androgens at 
puberty. Mutations are located in HSD3B2 in regions coding
for domains crucial for enzyme function (134,141). Smith-
Lemli Opitz syndrome is a dysmorphic disorder with 
microcephaly, short nose, pyloric stenosis and cleft palate.
Cholesterol synthesis fails at the 7-dehydrocholesterol 
reduction step and 7-dehydro steroids can be found in the 
urine of an infant with this condition (142). 
The further investigation of males with poor androgenisation
and normal cortisol will depend upon the initial findings for
testosterone and gonadotrophins. A low basal testosterone
with elevated gonadotrophins and a poor androgen response
to HCG suggest either Leydig cell hypoplasia (LCH) or an 
androgen biosynthetic defect. Mutations in the LH receptor
gene are responsible for LCH (143,144). A high ratio of 
androstenedione to testosterone in the basal state, exagera-
ted or revealed by HCG stimulation (ratio >2) suggests a 
defect of 17-ketosteroid reductase and genetic testing of
17BHSD3 may be needed (145-147). The immunoassays in
use for androgens are not accurate in young children. A male
with this defect can be reared as a boy but will need 
testosterone treatment. Improved, simultaneous androgen
assays by tandem mass spectrometry will aid the diagnosis of
DSD (148-151).
A normal basal testosterone with a rise following HCG
suggests that the problem is due to impaired action of 
testosterone. This can be due to a failure of target tissue 
5α-reductase or to receptor defects. Specialist help will be
needed to resolve this problem. A high testosterone to 
5α-DHT ratio (>20) after HCG stimulation supports 5α-reductase
deficiency. In a urine steroid profile there is evidence for this
disorder also in the distribution of cortisol metabolites 
(5α-THF to THF) in childhood. In newborns, however, the 
majority of cortisol metabolites have been oxidised to cortisone
metabolites and there is very little of the cortisol metabolites
to effectively confirm this diagnosis. This test should therefore
not be performed in the first six months. In that period, blood
samples for androgens can be taken, because LH secretion
is not suppressed (152). Missense and nonsense mutations
in SRD5A2 have been reported (153,154). Androgen receptor
defects can influence the number and stability of androgen
receptors. Genital skin needs to be taken and sent to a 
specialist laboratory. The cells have to be increased in 
number by culturing through several passages in tissue 
culture before these experiments can be undertaken. 
Receptor gene analysis is available in a few centres 
(155-159). Increased ratios of 5α to 5β reduced androgens
have been found in association with Serkal syndrome (sex 
reversal with dysgenesis of kidneys, adrenals and lungs) 
possibly reflecting increased 5α-reductase and loss of 
function of WNT4 signalling (160).
Males with defects in androgen action may be considered
for rearing as female. Mutations in SF-1 should be screened
in cases of suspected partial androgen insensitivity when no
mutations are found in the androgen receptor gene (161).
Mutations in SF-1 have been found in boys with hypospadias
or delayed puberty and no history of adrenal failure (162). 
Mutations in the gene for DAX-1 are found in boys that fail to
undergo puberty with hypogonadotrophic hypogonadism and
history of neonatal adrenal insufficiency without ambiguous
genitalia (47,48,55). GnRH deficiency results from failure of
embryonic migration of cells from the olfactory lobe to the 
forebrain. This is associated with anosmia in most cases
(Kallman’s syndrome) and five genes have been implicated
through mutation analysis of FGFR1, FGF8, PROKR2 and
KAL 1 (163) and CHD7 (164). A mutation in the GnRH 
receptor gene has been described (165).
Inhibin B and AMH are respective markers of Leydig and
Sertoli cell function. AMH concentrations are high in the first
month of life (3.2-68.5 ng/ml) (166) and fall during childhood
up to puberty (0.5-22.5 ng/ml). AMH is low in gonadal 
dysgenesis  (167), partial androgen insensitivity syndrome
and when there are mutations in the gene affecting AMH
production  (168). AMH is high when there are defects in 
testosterone synthesis and complete androgen insensitivity
(167,168). Inhibin B is at highest concentrations in infancy
(100-500 nm/ml), low during childhood (<50 ng/ml) then 
rise in the early stages of puberty along with the increase 
in serum testosterone and testicular volume (169,170). 
Basal AMH levels are high in androgen insensitivity 
syndrome (171).
Puberty is said to be delayed when there are no signs of
puberty in boys by the sixteenth year and fourteenth year in
girls (172). Complete absence of clinical signs in girls by the
fifteenth year warrant investigation. The causes of delayed
puberty are many. Gonadotrophin measurements will 
distinguish primary and secondary forms. The most common
problem is isolated gonadotrophin deficiency; in short 
children this may be constitutional delay of normal puberty.
The initial endocrine assessment of amenorrhoea includes
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thyroxine. Hyperthyroidism is occassionally associated with
amenorrhoea. When the serum prolactin exceeds 1000 iu/L,
a prolactin secreting adenoma needs to be confirmed by 
appropriate scanning techniques. Hyperprolactinaemia is a
cause of arrested puberty and successful medical or surgical
treatment will restore regular cycles. Disordered ovarian
function presents with primary amenhorroea. In some 
patients this can co-exist with signs of androgenisation. Body
size and degree of exercise are important clinical considerations.
Failure to show growth of the uterus on ultrasound also 
provides valuable diagnostic information. Failure to have a
menstrual bleed following a progestogen challenge test is
usually a further indication of low oestrogen production (poor
follicular growth). A karyotype will exclude Turner syndrome
and Turner mosaic. Low serum LH and FSH suggests 
hypogonadotrophic hypogonadism and these patients can
respond well to pulsatile GnRH treatment. Inactivating 
mutations of the FSH receptor have been found in a few 
patients with hypergonadotrophic hypogonadism (173).
When LH is raised in the presence of low or normal FSH, the
most likely diagnosis is polycystic ovaries (rarely indicative of
pregnancy due to reaction of HCG in the LH assay). Patients
with PCO may have oligomenorrhoea and have a characteristic
ovarian picture on ultrasound, and may have elevated LH
concentrations such that the LH to FSH ratio is 3 or more.   
When primary amenorrhoea is associated with hirsutism,
measurements of testosterone, DHAS, 17α-hydroxyproges-
terone, cortisol and prolactin are required to identify or 
exclude major causes of  abnormal androgen production. 
Serum testosterone >5 nmol/L is indicative of a rare ovarian
tumour. DHAS >20 mmol/L suggests the possibility of an 
adrenal androgen secreting tumour. 17α-hydroxyprogesterone
>5 nmol/L is an indication of some degree of adrenal 
21-hydroxylase defect. An ACTH stimulation test with 
exagerated response of 17OH-P is required to confirm this 
disease. The patient may be a heterozygote for the classical
disease or may have a milder form sometimes referred to as
late onset CAH. In very specialised laboratories 21-deoxycortisol
is a better marker for a defective 21-hydroxylase. These 
patients can be treated with glucocorticoids.
Delayed puberty in boys requires similar investigations of
the hypothalamic-pituitary-gonadal axis. Height and testicular
volume should be measured. Serum testosterone shoud be
measured early in the morning. Testicular failure can be due to
torsion, surgery or inflammation. Gonadotrophin deficiency can
be due to syndromes such as Kallman’s syndrome, A prolacti-
noma or pituitary hormone deficiency may be uncovered. 
A cranial MRI scan may be needed. Prader-Willi and Lawrence-
Moon-Biedel. Kallman’s syndrome is associated with anosmia.
During the last 20 years mutations in many genes in GnRH 
neuronal embryogenesis (KAL1, GnRHR, FGFR1, GPR54,
PROK2, PROK2R, FGF8, CHD7, TAC3, TAC3R, NELF)
(174,175) and pituitary development (Prop1, HESX1, POUF1,
LHX3, LHX4, SOX2, SOX3) (176-182) have been indentified. 
Summary
This review has covered the clinical problems in children
associated with steroid hormones. The excess or absence of
cortisol, aldosterone and sex steroids were dealt with in turn
so as to rationalise diagnostic tests.  The literature cited for 
reference includes many recent review articles. The laboratory
will contribute to future improvements in assays with
improved specificity and accuracy that will aid the differential
diagnosis of related diseases, elucidate the causes of common
clinical problems and further our understanding of 
developmental milestones such as adrenarche and puberty.
The search for genes involved in endocrine function and 
development continues at a pace and new factors will come to
light even between the time of writing this article and 
publication. This makes a review of this nature difficult to keep
totally up to date.
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